With the mega pharma mergers that keep cropping up and are likely to continue into the future, what is the impact felt by CROs?
What normally happens after merging of two big pharma companies is always a round of laying off and re-organization. Also, the combined pipelines would be trimmed as a result of the mergers. Such changes could negatively impact the late stage drug development CRO business due to the re-prioritizing of the pipelines. However, for the early stage (pre-clinical and discovery etc.) CRO business such changes could bring more business because of the increasing trend of outsourcing research and discovery to CROs after major re-orgs.
Liqiang Yang. Ph. D.
Chief Strategy Officer,
Rapid Novor, Inc.